Publication details

Mechanism of immunomodulatory drugs in multiple myeloma

Authors

SEDLAŘÍKOVÁ Lenka KUBICZKOVÁ Lenka ŠEVČÍKOVÁ Sabina HÁJEK Roman

Year of publication 2012
Type Article in Periodical
Magazine / Source Leukemia Research
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1016/j.leukres.2012.05.010
Field Oncology and hematology
Keywords Multiple myeloma; Treatment; Immunomodulatory drugs; Thalidomide; Lenalidomide; Pomalidomide
Attached files
Description Multiple myeloma is the second most common hematological cancer in the world. It is characterized by accumulation of malignant plasma cells in the bone marrow, osteolytic lesions and monoclonal immunoglobulins in blood/urine. With the introduction of immunomodulatory drugs into the treatment protocol, the outcome of multiple myeloma patients has dramatically improved with more than 30% of patients surviving for 10 years thus shifting multiple myeloma to a treatable condition.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info